Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Axsome Thera
(NQ:
AXSM
)
87.99
+0.88 (+1.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axsome Thera
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
June 03, 2022
These biotech stocks face some key make-or-break events in June that could have big implication for their futures.
Via
InvestorPlace
Axsome Therapeutics, Inc. Investor News: Robbins LLP is Investigating Axsome Therapeutics, Inc. (AXSM) on Behalf of Shareholders
June 01, 2022
From
Robbins LLP
Via
Business Wire
NATIONALLY RANKED ROSEN LAW FIRM Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM
May 28, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Where Axsome Therapeutics Stands With Analysts
May 03, 2022
Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter:
Via
Benzinga
As Expected, FDA Rejects Axsome Therapeutics' Migraine Candidate
May 02, 2022
Via
Benzinga
Recap: Axsome Therapeutics Q1 Earnings
May 02, 2022
Axsome Therapeutics (NASDAQ:AXSM) reported its Q1 earnings results on Monday, May 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
May 26, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
May 24, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
May 23, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) Investors
May 23, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTOR DEADLINE: Axsome Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AXSM
May 21, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
AXSM Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Axsome Therapeutics, Inc. (AXSM)
May 20, 2022
From
Robbins LLP
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) Investors
May 20, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) Investors
May 19, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Investors to Contact the Firm
May 19, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors
May 18, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
Shareholder Alert: Did You Purchase Shares of Axsome Therapeutics, Inc. (AXSM)? Robbins LLP Alerts Investors of Class Action Against Axsome Therapeutics, Inc.
May 18, 2022
From
Robbins LLP
Via
Business Wire
AXSOME ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages Investors to Contact the Firm
May 17, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors
May 17, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors
May 17, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm
May 17, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Axsome Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AXSM
May 16, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. With Losses of $500,000 to Contact the Firm
May 16, 2022
From
The Schall Law Firm
Via
Business Wire
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
May 16, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?
May 09, 2022
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S.
Via
Benzinga
FDA Issues Complete Response Letter (CRL) to Axsome Therapeutics for AXS-07 In Acute Migraine
May 02, 2022
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Axsome Therapeutics, Inc. (NASDAQ: AXSM) regarding its New Drug Application (NDA) for AXS-07 for the acute...
Via
Benzinga
5 Trending Tickers On Benzinga For May 2, 2022: Activision, SoundHound And More
May 02, 2022
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...
Via
Benzinga
A Preview Of Axsome Therapeutics's Earnings
April 29, 2022
Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings report on Monday, 2022-05-02. Here's what investors need to know before the announcement. Analysts estimate that Axsome...
Via
Benzinga
92 Biggest Movers From Friday
May 09, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...
Via
Benzinga
Earnings Scheduled For May 2, 2022
May 02, 2022
Companies Reporting Before The Bell • New Gold (AMEX:NGD) is estimated to report quarterly earnings at $0.03 per share on revenue of $212.42 million.
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.